Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 27;6(1):19.
doi: 10.1186/s40635-018-0185-2.

Ecological effects of cefepime use during antibiotic cycling on the Gram-negative enteric flora of ICU patients

Affiliations

Ecological effects of cefepime use during antibiotic cycling on the Gram-negative enteric flora of ICU patients

Carola Venturini et al. Intensive Care Med Exp. .

Abstract

This study examines the impact of cefepime and APP-β (antipseudomonal penicillin/ β-lactamase inhibitor combinations) on Gram-negative bacterial colonization and resistance in two Australian ICUs. While resistance did not cumulatively increase, cefepime (but not APP-β treatment) was associated with acquisition of antibiotic resistant Enterobacteriaceae, consistent with an ecological effect. Analysis of the resident gut E. coli population in a subset of patients showed an increase in markers of horizontal gene transfer after cefepime exposure that helps explain the increase in APP-β resistance and reminds us that unmeasured impacts on the microbiome are key outcome determinants that need to be fully explored.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The previously published clinical component in the parent study (Ginn et al. 2012 [5]) was conducted under a waiver of consent, under the auspices of the relevant Human Research Ethics Committees of the Sydney West Area Health Service and the Royal Brisbane and Women’s Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Variation in colonization patterns before and after ICU stay. a Rates of colonization with antibiotic-resistant species at admission and after ICU stay. b Change in susceptibility rates after ICU stay in different treatment cycles. Proportion of the entire study group of patients (n = 206) with positive cultures. “Any resistance” indicates any bacterial growth on antibiotic supplemented media. “All resistance” indicates any growth on ChromAgar™ supplemented with vancomycin only (to exclude Gram-positive species). *KESC, Klebsiella, Enterobacter, Serratia, Citrobacter spp. as identified on colorimetric media ChromAgar™ and confirmed by MALDI-TOF [16] as previously described [5]. Asterisks (*, **, ***) above bar charts indicate significant differences (p < 0.05)
Fig. 2
Fig. 2
Antibiotic resistance markers detected before and after cefepime exposure in E. coli isolates from ICU patients. Resistance genes (a), plasmid replication genes (b), and plasmid transfer markers (c) were identified using the sequencing output from MiSeq sequencing (250 bp; paired-end) of pooled representatives (2–6 colonies per patient) of the E. coli population before (black) and after (white) cefepime treatment. Markers were detected by alignment with resistance genes and mobile genetic elements in the MARA database [17] and plasmids markers in our in-house database (Additional file 1 Methods). aad includes aadA1, aadA6, and aadA10; “transfer” comprises marker genes for conjugation/self-transmission (tra, nik, etc.); “mobilization” indicates relaxase genes of mobilizable plasmid types (Additional file 1: Table S1) [18]

Similar articles

Cited by

References

    1. Lankelma JM, van Vught LA, Belzer C, Schultz MJ, van der Poll T, de Vos WM, Wiersinga WJ. Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study. Intensive Care Med. 2016;43(1):59–68. doi: 10.1007/s00134-016-4613-z. - DOI - PMC - PubMed
    1. Macfarlane S. Antibiotic treatments and microbes in the gut. Environ Microbiol. 2014;16(4):919–924. doi: 10.1111/1462-2920.12399. - DOI - PubMed
    1. Kalil AC. Is cefepime safe for clinical use? A Bayesian viewpoint. J Antimicrob Chemother. 2011;66(6):1207–1209. doi: 10.1093/jac/dkr138. - DOI - PubMed
    1. Arizpe A, Reveles KR, Patel SD, Aitken SL. Updates in the management of cephalosporin-resistant Gram-negative bacteria. Curr Infect Dis Rep. 2016;18(12):39. doi: 10.1007/s11908-016-0552-7. - DOI - PMC - PubMed
    1. Ginn AN, Wiklendt AM, Gidding HF, George N, O’Driscoll JS, Partridge SR, O’Toole BI, Perri RA, Faoagali J, Gallagher JE, Lipman J, Iredell JR. The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not Tazocin selects for antibiotic resistant infection. PLoS One. 2012;7(6):e38719. doi: 10.1371/journal.pone.0038719. - DOI - PMC - PubMed

LinkOut - more resources